Products & Services · Total revenues
JAKAFI — Total revenues
Incyte JAKAFI — Total revenues decreased by 8.5% to $757.76M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 6.8%, from $709.41M to $757.76M. Over 4 years (FY 2021 to FY 2025), JAKAFI — Total revenues shows an upward trend with a 9.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2017
Last reportedQ1 2026Apr 28, 2026
Rolls up toTotal Revenue
How to read this metric
An increase indicates strong market demand and successful commercialization, while a decrease may signal market saturation or increased competition.
Detailed definition
This metric represents the total gross revenue generated from the sales of a specific pharmaceutical product within a de...
Peer comparison
Standard across all pharmaceutical companies reporting product-level revenue.
Metric ID:
incy_segment_jakafi_total_revenuesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $529.06M | $547.37M | $592.37M | $544.46M | $597.67M | $619.60M | $647.49M | $579.97M | $682.38M | $636.25M | $695.13M | $571.84M | $705.97M | $741.18M | $773.11M | $709.41M | $763.79M | $791.07M | $828.24M | $757.76M |
| QoQ Change | — | +3.5% | +8.2% | -8.1% | +9.8% | +3.7% | +4.5% | -10.4% | +17.7% | -6.8% | +9.3% | -17.7% | +23.5% | +5.0% | +4.3% | -8.2% | +7.7% | +3.6% | +4.7% | -8.5% |
| YoY Change | — | — | — | — | +13.0% | +13.2% | +9.3% | +6.5% | +14.2% | +2.7% | +7.4% | -1.4% | +3.5% | +16.5% | +11.2% | +24.1% | +8.2% | +6.7% | +7.1% | +6.8% |
Range$529.06M – $828.24M
CAGR+7.9%
Avg YoY Growth+9.3%
Median YoY Growth+7.8%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's jakafi — total revenues?
- Incyte (INCY) reported jakafi — total revenues of $757.76M in Q1 2026.
- How has Incyte's jakafi — total revenues changed year-over-year?
- Incyte's jakafi — total revenues increased by 6.8% year-over-year, from $709.41M to $757.76M.
- What is the long-term trend for Incyte's jakafi — total revenues?
- Over 4 years (2021 to 2025), Incyte's jakafi — total revenues has grown at a 9.7% compound annual growth rate (CAGR), from $2.13B to $3.09B.
- What does jakafi — total revenues mean?
- The total sales revenue generated by a specific drug product.